目的 探討強(qiáng)骨生血口服液聯(lián)合骨化三醇治療婦女絕經(jīng)后骨質(zhì)疏松的臨床療效。方法 選取2022年6月—2023年6月在武漢市中醫(yī)院診治的124例絕經(jīng)后骨質(zhì)疏松患者，隨機(jī)分為對照組（62例）和治療組（62例）。對照組患者口服骨化三醇膠丸，0.25 µg/次，2次/d。在對照組的基礎(chǔ)上，治療組口服強(qiáng)骨生血口服液，30 mL/次，3次/d。兩組患者連服12周。觀察兩組患者臨床療效，比較治療前后兩組患者癥狀好轉(zhuǎn)時間，骨代謝指標(biāo)骨鈣蛋白（BGP）、骨堿性磷酸酶（BALP）、骨保護(hù)素（OPG）和N-端骨鈣素（N-MID）水平及血清胰島素樣生長因子-1（ICF-1）、C反應(yīng)蛋白（CRP）、腫瘤壞死因子-α（TNF-α）和白細(xì)胞介素-6（IL-6）水平。結(jié)果 治療后，治療組臨床總有效率為98.39%，明顯高于對照組（83.87%，P＜0.05）。治療后，治療組癥狀好轉(zhuǎn)時間均明顯短于低于對照組（P＜0.05）。治療后，兩組患者BGP、BALP、OPG和ICF-1水平明顯升高，而N-MID、IL-6、TNF-α、CRP水平明顯降低（P＜0.05），且治療組這些指標(biāo)水平明顯好于對照組（P＜0.05）。結(jié)論 強(qiáng)骨生血口服液聯(lián)合骨化三醇治療效果確切，能顯著緩解臨床癥狀，有效提高骨代謝能力，并促進(jìn)機(jī)體炎癥反應(yīng)減弱。

Objective To investigate the clinical efficacy of Qianggu Shengxue Oral Liquid combined with calcitriol in treatment of postmenopausal osteoporosis. Methods Patients (124 cases) with postmenopausal osteoporosis in Wuhan Hospital of Traditional Chinese Medicine from June 2022 to June 2023 were randomly divided into control (62 cases) and treatment (62 cases) group. Patients in the control group were po administered with Calcitriol Soft Capsules, 0.25 µg/time, twice daily. Patients in the treatment group were po administered with Qianggu Shengxue Oral Liquid on the basis of the control group, 30 mL/time, three times daily. Patients in two groups were treated for 12 weeks. After treatment, the clinical evaluations was evaluated, the time of symptom relief, the levels of bone metabolic markers BGP, BALP, OPG and N-MID, the serological IL-6, TNF-α, CRP and ICF-1 levels in two groups before and after treatment were compared. Results After treatment, the clinical effective rate in the treatment group was 98.39%, which was significantly higher than that of the control group (83.87%, P＜0.05). After treatment, the time of symptom improvement in the treatment group was significantly shorter than that in the control group (P＜0.05). After treatment, the levels of BGP, BALP, OPG and ICF-1 were significantly increased, while the levels of N-MID, IL-6, TNF-α and CRP were significantly decreased in two groups, and these indexes in the treatment group were significantly better than those in the control group (P＜0.05). Conclusion Qianggu Shengxue Oral Liquid combined with calcitriol in treatment of postmenopausal osteoporosis has a definite therapeutic effect, which can significantly relieve clinical symptoms, effectively improve bone metabolism, and promote the weakening of inflammatory reaction.

R982

湖北省衛(wèi)生健康委員會科研項目（WJ2019F163）